IPO
Legend Biotech, a clinical stage oncology biotech company, filed with the U.S. Securities and Exchange Commission on Wednesday to raise up to $100 million in an initial public offering.
Four months after raising $30 million in a Series C financing round, Watertown, Mass.-based Lyra Therapeutics raised an additional $56 million in its initial public offering.
Company enters next development phase with management expansion and implementation of a Strategic and Scientific Advisory Board
Heidelberg Pharma AG announces that it has successfully raised approximately EUR 14.4 million in gross proceeds through a private placement via an accelerated book building transaction.
FoRx Therapeutics AG, the biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress pathways, announced the closing of a EUR 10 million seed financing led by M Ventures, Novartis Venture Fund and Omega Funds.
Despite booming commercial interest in plant-based and cultivated meat, funding for academic research lags behind, and the industries lack the open-access data required to overcome technical hurdles and scale up to become a viable part of the global food system.
Proceeds support advancing clinical development of next-generation cancer immunotherapies targeting A2A adenosine receptor and anti-TIGIT immune checkpoint
4BIO Capital, an international venture capital firm focused solely on the advanced therapies sector, announces its investment in Redpin Therapeutics, Inc., a pioneering chemogenetics company developing drug-controlled gene therapies to address intractable diseases of the nervous system.
Heidelberg Pharma AG published its financial results and annual report for fiscal year 2019 and its outlook for 2020.
Priority Review for BLA submission was granted by U.S. FDA for tafasitamab in combination with lenalidomide for relapsed/refractory diffuse large B cell lymphoma (r/r DLBCL) based on positive primary analysis data of L-MIND and Re-MIND studies
PRESS RELEASES